Effect of age and frailty on the efficacy and tolerability of once‐weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Effect of age and frailty on the efficacy and tolerability of once‐weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma
Authors
Keywords
-
Journal
AMERICAN JOURNAL OF HEMATOLOGY
Volume 96, Issue 6, Pages 708-718
Publisher
Wiley
Online
2021-03-23
DOI
10.1002/ajh.26172
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials
- (2020) Maria Gavriatopoulou et al. LEUKEMIA
- Validation of the FIRST simplified frailty scale using the ECOG performance status instead of patient-reported activities
- (2020) Claudia A. M. Stege et al. LEUKEMIA
- Validation of the revised myeloma comorbidity index and other comorbidity scores in a multicenter German study group multiple myeloma trial
- (2020) Sandra Maria Dold et al. HAEMATOLOGICA
- Structured assessment of frailty in multiple myeloma as a paradigm of individualized treatment algorithms in cancer patients at advanced age
- (2020) Monika Engelhardt et al. HAEMATOLOGICA
- Carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) for initial therapy of newly diagnosed multiple myeloma (NDMM): Results of ENDURANCE (E1A11) phase III trial.
- (2020) Shaji Kumar et al. JOURNAL OF CLINICAL ONCOLOGY
- Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial
- (2020) Maria-Victoria Mateos et al. Lancet Haematology
- Defining the vulnerable patient with myeloma—a frailty position paper of the European Myeloma Network
- (2020) Gordon Cook et al. LEUKEMIA
- Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial
- (2020) Nagesh Kalakonda et al. Lancet Haematology
- A clinical prediction model for outcome and therapy delivery in transplant-ineligible patients with myeloma (UK Myeloma Research Alliance Risk Profile): a development and validation study
- (2019) Gordon Cook et al. Lancet Haematology
- Challenges and Strategies in the Management of Multiple Myeloma in the Elderly Population
- (2019) Saurabh Zanwar et al. Current Hematologic Malignancy Reports
- Aberrant Wnt signaling in multiple myeloma: molecular mechanisms and targeting options
- (2019) Harmen van Andel et al. LEUKEMIA
- Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma
- (2019) Andrzej J. Jakubowiak et al. BRITISH JOURNAL OF HAEMATOLOGY
- miR-23b-3p suppressing PGC1α promotes proliferation through reprogramming metabolism in osteosarcoma
- (2019) Ran Zhu et al. Cell Death & Disease
- Subcutaneous Delivery of Daratumumab in Relapsed or Refractory Multiple Myeloma
- (2019) Saad Z. Usmani et al. BLOOD
- A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial
- (2019) Thierry Facon et al. LEUKEMIA
- Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma
- (2019) Ajai Chari et al. NEW ENGLAND JOURNAL OF MEDICINE
- The relative importance of factors predicting outcome for myeloma patients at different ages: results from 3894 patients in the Myeloma XI trial
- (2019) Charlotte Pawlyn et al. LEUKEMIA
- Clinical Implications of Targeting XPO1-mediated Nuclear Export in Multiple Myeloma
- (2018) Ujjawal H. Gandhi et al. Clinical Lymphoma Myeloma & Leukemia
- Multiple myeloma: 2018 update on diagnosis, risk-stratification, and management
- (2018) S. Vincent Rajkumar AMERICAN JOURNAL OF HEMATOLOGY
- Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma
- (2018) Nizar J. Bahlis et al. BLOOD
- A concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients
- (2017) Monika Engelhardt et al. HAEMATOLOGICA
- XPO1 in B cell hematological malignancies: from recurrent somatic mutations to targeted therapy
- (2017) Vincent Camus et al. Journal of Hematology & Oncology
- Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial
- (2017) Brian G M Durie et al. LANCET
- Epigenetic strategies to reverse drug resistance in heterogeneous multiple myeloma
- (2017) Mark E. Issa et al. Clinical Epigenetics
- A concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients
- (2017) Monika Engelhardt et al. HAEMATOLOGICA
- N-terminal fragment of the type-B natriuretic peptide (NT-proBNP) contributes to a simple new frailty score in patients with newly diagnosed multiple myeloma
- (2016) Paolo Milani et al. AMERICAN JOURNAL OF HEMATOLOGY
- International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
- (2016) Shaji Kumar et al. LANCET ONCOLOGY
- Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma
- (2016) Meletios A. Dimopoulos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Concise review ‐ Treatment of multiple myeloma in the very elderly: How do novel agents fit in?
- (2016) Nicolas Kint et al. Journal of Geriatric Oncology
- Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report
- (2015) A. Palumbo et al. BLOOD
- Trends in autologous hematopoietic cell transplantation for multiple myeloma in Europe: increased use and improved outcomes in elderly patients in recent years
- (2014) H W Auner et al. BONE MARROW TRANSPLANTATION
- Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials
- (2013) S. Bringhen et al. HAEMATOLOGICA
- Assessment of Vulnerability Measures and Their Effect on Survival in a Real-Life Population of Multiple Myeloma Patients Registered at Marche Region Multiple Myeloma Registry
- (2012) Massimo Offidani et al. Clinical Lymphoma Myeloma & Leukemia
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now